[ad_1]
This morning the fourth vaccine, from the British-Swedish manufacturer “AstraZeneca”, which is often called the “Oxford” vaccine, arrived in Serbia.
The vaccine was developed by the University of Oxford and the British-Swedish company Astra Zeneca.
Like the Chinese and Russian vaccines, the Oxford vaccine is one of the vector vaccines because it is made from adenovirus.
This vaccine contains a genetically modified virus. It has been modified to prevent human infection, but it still contains part of the corona virus, the spikey protein. When injected into the human body, it begins to produce a spikey corona virus, which the immune system recognizes as a threat and attempts to destroy.
After that, when the immune system comes into contact with the real corona virus, the body already knows how to behave and act.
Studies have shown that the Oxford vaccine stops COVID symptoms in 70 percent of cases, and according to some data, by refining the vaccine, protection could go up to 90 percent.
Following the discovery of a new strain of the virus in the UK, AstraZeneca CEO Pascal Sorio said the company’s vaccine was also effective against the British crown strain.
Easier to deliver
When it comes to distribution, the Oxford vaccine stands out as one of the easiest to deliver and store, and that’s one reason it could speed up the immunization process.
It can be stored at normal refrigerator temperature for at least six months, which is a major difference compared to the Pfizer vaccine, which should be stored at about minus 70 degrees.
Experts from Serbia also participated in the development of the vaccine at Oxford.
British Ambassador Shan McLeod stated at Belgrade’s “Nikola Tesla” airport, where the first batch of vaccines from the British-Swedish manufacturer “AstraZenek” of 150,000 doses arrived, that young experts from Serbia also participated in the development of this vaccine in Oxford. .
– I’m glad to be here and to have waited for the arrival of this vaccine. The vaccine was developed at the University of Oxford and an international team worked on it. Among them are young scientists from Serbia – said McLeod.
Dr. Gnjatović on the Oxford vaccine
Marija Gnjatović from the Institute for Nuclear Energy Application said that AstraZeneka is very similar to the Sputnik V vaccine, which is a vector vaccine, adding that Spunjik has proven to be quite effective.
– We tested the effectiveness of this vaccine on a small sample of doctors, in terms of creating antibodies. In our examined group, 100 people developed antibodies against the Sputnik V vaccine, and since they are very similar, I expect equally good results with the AstraZenek vaccines, Gnjatović said.
As he says, smart technology was used for this vaccine, to insert the protein of this SARS COV2 virus into a harmless virus, and its function, as he says, is only to transmit information about that virus.
– The technology is very similar to the Russian one, now some research is being done to combine these two vaccines. They can be combined and the first efficiency results are expected in early May, Gnjatović said.
According to her, research has shown that the efficiency is good for now and that 100 percent of people have developed antibodies against the Russian vaccine.
Combined use with Russian vaccine
The Russian institute Gamaleja, which developed the vaccine against kovid-19 Sputnik V, confirmed in a post on Twitter the start of clinical trials of the combined use of its own and the AstraZeneca vaccine.
– The use of Sputnik V vaccine as the second dose of the AstraZeneca vaccine eliminates the need to wait 3 months. Clinical trials of this approach have already begun; it’s written in the ad on Sputnik V’s Twitter account, according to the agency.
Problems with delivery in the EU
In late January, the European Medicines Agency approved the Oxford vaccine for use in the EU. However, suspicions about the widespread craze for vaccines soon came true, and thus conflicts.
As Europe waited for the “AstraZenek” vaccine like the freezing sun, the company announced that it would be delayed with delivering the vaccine even before receiving permission for use on January 29.
In other words, the company affirmed that due to the “production stoppage”, the EU will be able to deliver 31 million doses of its vaccine in the first quarter of this year, although the distribution of some 80 million vaccines was agreed at the end of March.
This information completely infuriated the Europeans as they agreed to pay AstraZeneca around $ 408 million in advance to help them speed up vaccine production, so the EU, as well as individual countries, announced lawsuits against the company.
(Kurir.rs)
delivery courier
Author: delivery courier
[ad_2]
